s being deposited with the I hereby certifunat this correspond stal Service as first class mail in an envelope Assistant Commissioner for Patents, Box AF United States P addressed to the Washington, D.C. 2020 2020

RECEIVED

JUL 1 1 2002

TECH CENTER 1600/2900

Printed: Carolyn C. Caires

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: RISER and DENICHILO

Assignee:

FibroGen, Inc.

Title: METHODS FOR DIAGNOSING RENAL DISORDERS

Serial No.

09/392,024

Filing Date:

08 September 1999

Examiner:

P. Nolan

Group Art Unit: 1644

Assistant Commissioner for Patents

Box AF

Washington, D.C. 20231

AMENDMENT

Sir:

In response to the final Office Action dated 8 April 2002, please consider the above-identified application in view of the following amendments and remarks.

IN THE CLAIMS

Please enter rewritten claims 14 and 17 as follows:

- 14. (Thrice Amended) A method for diagnosing a renal disorder characterized by overproduction of extracellular matrix, or identifying a predisposition or susceptibility to a renal disorder characterized by overproduction of extracellular matrix, in a subject, the method comprising:
 - (a) obtaining a sample from the subject;
 - (b) detecting the level of CTGF protein in the sample; and
 - (c) comparing the level of CTGF protein in the sample to a standard level of CTGF protein, wherein increased levels of CTGF protein are indicative of the presence of a renal disorder.
- 17. (Twice Amended) A diagnostic kit for use in diagnosing a renal disorder characterized by overproduction of extracellular matrix, or identifying a predisposition or susceptibility to a renal disorder characterized by overproduction of extracellular matrix, the method comprising:

1

- (a) a means for detecting the level of CTGF protein in a sample; and
- (b) a means for measuring the level of CTGF protein in the sample.